Differential response to neoadjuvant endocrine therapy for Black/African American and White women in NCDB
ConclusionIndependent of NET duration and clinical stage at presentation, BAA women were more likely to experience both complete tumor response and progression to metastatic disease. These results suggest significant heterogeneity in tumor biology and warrant a more nuanced therapeutic approach to HR  + BC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 1, 2024 Category: Cancer & Oncology Source Type: research

Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
ConclusionThe concordance between luminal subtypes determined by three different IHC-based classifiers and the nCOUNTER PAM50 assay was suboptimal. Thus, a significant proportion of luminal A and B tumors as determined by the surrogate classifiers could be undertreated or over-treated. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 1, 2024 Category: Cancer & Oncology Source Type: research

Low incidence of distant metastases in older women with non-metastatic breast cancer treated with primary endocrine therapy
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 1, 2024 Category: Cancer & Oncology Source Type: research

Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 1, 2024 Category: Cancer & Oncology Source Type: research

Long-term breast cancer incidence trends by mammography, obesity, and menopausal hormone therapy
ConclusionThe sustained reduction in hormone therapy use from 2003 provides a plausible explanation for most of the lower breast cancer incidence seen in US postmenopausal women during the last two decades. The strong observational study obesity association with higher breast cancer risk is not reflected in breast cancer incidence trends. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 1, 2024 Category: Cancer & Oncology Source Type: research

Retraction Note: Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 1, 2024 Category: Cancer & Oncology Source Type: research

Subspecialized breast pathologists have suboptimal interobserver agreement in Ki-67 evaluation using 20% as the cutoff
ConclusionThe modified IKWG algorithm does not significantly improve interobserver agreement. A better algorithm or assistance from digital image analysis is needed to improve interobserver variability in Ki-67 evaluation. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 29, 2023 Category: Cancer & Oncology Source Type: research

Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer
ConclusionsAmong stage III IBC patients, pCR rates were similar, irrespective of the NAC lines number, and BCFS and OS were comparable with pCR after 1L and 2-3L. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 28, 2023 Category: Cancer & Oncology Source Type: research

Social inequalities in the use of physiotherapy in women diagnosed with breast cancer in Barcelona: DAMA cohort
ConclusionsSocial and economic inequalities exist on the access to physiotherapy by women diagnosed with breast cancer, which is generally low, and may clearly impact on their functional recovery. Promoting strategies to reduce social bias, as well as improve communication and patient information regarding physiotherapy may be of interest for a better health care in breast cancer diagnosed women. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 28, 2023 Category: Cancer & Oncology Source Type: research

Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers
ConclusionThis is the largest investigation of thePIK3R1 mutational landscape in breast cancer patients (n  = 6,009).PIK3R1 mutations were more common in triple-negative breast cancer (~  6%) than in HER2 + or HER2-/HR + disease (approximately 2%). While alterations in the PI3K/AKT pathway are often actionable in HER2-/HR + breast cancer, our study suggests thatPIK3R1 could be an important target in TNBC as well. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 28, 2023 Category: Cancer & Oncology Source Type: research

Correction: FN1-mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 28, 2023 Category: Cancer & Oncology Source Type: research

Second primary cancers among females with a first primary breast cancer: a population-based study in Northern Portugal
ConclusionIn Portugal, patients with a breast FPC have a higher incidence of cancer compared to the general female population, highlighting important aspects of care, surveillance, and counselling among this growing number of patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 27, 2023 Category: Cancer & Oncology Source Type: research

Is there an association between endometriosis and subsequent breast cancer? A retrospective cohort study from Germany
ConclusionIn summary, our comprehensive 10-year study involving a substantial sample of women indicates that endometriosis is not significantly associated with an increased risk of subsequent breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 23, 2023 Category: Cancer & Oncology Source Type: research

Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study
ConclusionThis study suggests that both cN-status and ypN-status, and molecular subtype should be considered to further improve prognostication. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 22, 2023 Category: Cancer & Oncology Source Type: research

Survival, treatment patterns, and costs of HER2+  metastatic breast cancer patients in Ontario between 2005 to 2020
ConclusionThe baseline characteristics and treatment patterns for patients who received HER2-TT in our study align with previously reported results. However, the mOS observed for 2L T-DM1 was shorter than that found in pivotal, clinical trial literature. As expected, anti-cancer systemic therapy costs were the main contributor to the over quarter-million dollar mean cost per patient onpert_tras in 1L. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 21, 2023 Category: Cancer & Oncology Source Type: research